Tenth generic of thrombopoietin drug Revolade to enter Russian market - Новости GxP

Tenth generic of thrombopoietin drug Revolade to enter Russian market  Новости GxP

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other...

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies  Novartis

GSK receives marketing authorisation from the European Commission for additional Revolade - gsk.com

GSK receives marketing authorisation from the European Commission for additional Revolade  gsk.com

Generic Medicine OKd by Europe for Thrombocytopenia With HCV - Medscape

Generic Medicine OKd by Europe for Thrombocytopenia With HCV  Medscape

Type Analysis - market.us

Type Analysis  market.us

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia - koreabiomed.com

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia  koreabiomed.com

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia - NEJM

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia  NEJM

NICE thumbs-up for Revolade - Pharmafile

NICE thumbs-up for Revolade  Pharmafile

Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year an...

Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP  Novartis

Novartis bags EU approvals for three ex-GSK drugs - PMLiVE

Novartis bags EU approvals for three ex-GSK drugs  PMLiVE

New hope for ITP patients dashed by high drug cost - CBC

New hope for ITP patients dashed by high drug cost  CBC

NICE says yes to Grifols' Tavlesse for rare blood disorder ITP - pharmaphorum

NICE says yes to Grifols' Tavlesse for rare blood disorder ITP  pharmaphorum

GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepat...

GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection  gsk.com

Novartis’ Revolade proved effective for seniors - koreabiomed.com

Novartis’ Revolade proved effective for seniors  koreabiomed.com

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designati...

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication  Novartis

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic sy...

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes  gsk.com

Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocyto...

Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)  Novartis

GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe ap...

GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe aplastic anaemia  gsk.com

NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment i...

NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia  Novartis

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA) - Nov...

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)  Novartis

GSK guilty of off-label promotion - Pharmafile

GSK guilty of off-label promotion  Pharmafile

Novartis: Blood Disease Drugs Jakavi, Revolade Show Positive Study Results - finchannel.com

Novartis: Blood Disease Drugs Jakavi, Revolade Show Positive Study Results  finchannel.com

Novartis' patent on eltrombopag olamine upheld by Delhi High Court - The Pharma Letter

Novartis' patent on eltrombopag olamine upheld by Delhi High Court  The Pharma Letter

GSK’s Promacta extends US licence - Pharmafile

GSK’s Promacta extends US licence  Pharmafile

How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17 - Market Realist

How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17  Market Realist